Editorial: The Value of Monitoring Local Antimicrobial Resistance Patterns in Enteric Fever

• References

• 1 Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev 2015; 28 (04) 901-937
• 2 GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 2019; 19 (04) 369-381
• 3 Joshi D, Gupta V, Bhatt D. et al. Profile of enteric fever in children admitted to a tertiary care centre in North India. J Gastrointest Infect 2023 (e-pub ahead of print). DOI: 10.1055/s-0043-1774409
• 4 Qamar FN, Yousafzai MT, Khalid M. et al. Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study. Lancet Infect Dis 2018; 18 (12) 1368-1376
• 5 Effa EE, Lassi ZS, Critchley JA. et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2011; 2011 (10) CD004530
• 6 Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008; 8 (04) CD006083
• 7 Kuehn R, Stoesser N, Eyre D, Darton TC, Basnyat B, Parry CM. Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins. Cochrane Database Syst Rev 2022; 11 (11) CD010452
• 8 Pascual A, Conejo MC, García I, Perea EJ. Factors affecting the intracellular accumulation and activity of azithromycin. J Antimicrob Chemother 1995; 35 (01) 85-93
• 9 Matsumoto Y, Ikemoto A, Wakai Y, Ikeda F, Tawara S, Matsumoto K. Mechanism of therapeutic effectiveness of cefixime against typhoid fever. Antimicrob Agents Chemother 2001; 45 (09) 2450-2454